Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)

H.G. Shen; P.G. Halbur; T. Opriessnig; N.M. Beach; Y.W. Huang; X.J. Meng

doi:10.1016/j.vaccine.2010.07.002

Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)

H.G. Shen, P.G. Halbur, T. Opriessnig, N.M. Beach, Y.W. Huang, X.J. Meng

Royal (Dick) School of Veterinary Studies

Research output: Contribution to journal › Article › peer-review

Abstract

The efficacies of commercial porcine circovirus type 2 (PCV2) vaccines and a live PCV1-2a chimeric vaccine were compared in conventional, PCV2-positive piglets using a PCV2-porcine reproductive and respiratory syndrome virus (PRRSV)-porcine parvovirus (PPV) coinfection challenge model. Seventy-three, 2-week-old pigs were randomized into seven groups including five vaccinated and two control groups. Pigs in the vaccinated groups were vaccinated at 3 weeks (one dose) or at 3 and 6 weeks (two dose) of age. All vaccine regimens tested were effective in reducing naturally occurring PCV2 viremia at 16 weeks of age and after PCV2 challenge, demonstrating the capability of the products to induce a lasting protective immunity despite the presence of PCV2 viremia at the time of vaccination.

Original language	English
Pages (from-to)	5960-5966
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	37
DOIs	https://doi.org/10.1016/j.vaccine.2010.07.002
Publication status	Published - 1 Aug 2010

Access to Document

10.1016/j.vaccine.2010.07.002

Fingerprint

Dive into the research topics of 'Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)'. Together they form a unique fingerprint.

Cite this

Shen, H. G., Halbur, P. G., Opriessnig, T., Beach, N. M., Huang, Y. W., & Meng, X. J. (2010). Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV). Vaccine, 28(37), 5960-5966. https://doi.org/10.1016/j.vaccine.2010.07.002

@article{755d2f702ff04d72a59e753f2394bb0a,

title = "Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)",

abstract = "The efficacies of commercial porcine circovirus type 2 (PCV2) vaccines and a live PCV1-2a chimeric vaccine were compared in conventional, PCV2-positive piglets using a PCV2-porcine reproductive and respiratory syndrome virus (PRRSV)-porcine parvovirus (PPV) coinfection challenge model. Seventy-three, 2-week-old pigs were randomized into seven groups including five vaccinated and two control groups. Pigs in the vaccinated groups were vaccinated at 3 weeks (one dose) or at 3 and 6 weeks (two dose) of age. All vaccine regimens tested were effective in reducing naturally occurring PCV2 viremia at 16 weeks of age and after PCV2 challenge, demonstrating the capability of the products to induce a lasting protective immunity despite the presence of PCV2 viremia at the time of vaccination.",

author = "H.G. Shen and P.G. Halbur and T. Opriessnig and N.M. Beach and Y.W. Huang and X.J. Meng",

year = "2010",

month = aug,

day = "1",

doi = "10.1016/j.vaccine.2010.07.002",

language = "English",

volume = "28",

pages = "5960--5966",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "37",

}

Shen, HG, Halbur, PG, Opriessnig, T, Beach, NM, Huang, YW & Meng, XJ 2010, 'Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)', Vaccine, vol. 28, no. 37, pp. 5960-5966. https://doi.org/10.1016/j.vaccine.2010.07.002

Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV). / Shen, H.G.; Halbur, P.G.; Opriessnig, T. et al.

In: Vaccine, Vol. 28, No. 37, 01.08.2010, p. 5960-5966.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)

AU - Shen, H.G.

AU - Halbur, P.G.

AU - Opriessnig, T.

AU - Beach, N.M.

AU - Huang, Y.W.

AU - Meng, X.J.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The efficacies of commercial porcine circovirus type 2 (PCV2) vaccines and a live PCV1-2a chimeric vaccine were compared in conventional, PCV2-positive piglets using a PCV2-porcine reproductive and respiratory syndrome virus (PRRSV)-porcine parvovirus (PPV) coinfection challenge model. Seventy-three, 2-week-old pigs were randomized into seven groups including five vaccinated and two control groups. Pigs in the vaccinated groups were vaccinated at 3 weeks (one dose) or at 3 and 6 weeks (two dose) of age. All vaccine regimens tested were effective in reducing naturally occurring PCV2 viremia at 16 weeks of age and after PCV2 challenge, demonstrating the capability of the products to induce a lasting protective immunity despite the presence of PCV2 viremia at the time of vaccination.

AB - The efficacies of commercial porcine circovirus type 2 (PCV2) vaccines and a live PCV1-2a chimeric vaccine were compared in conventional, PCV2-positive piglets using a PCV2-porcine reproductive and respiratory syndrome virus (PRRSV)-porcine parvovirus (PPV) coinfection challenge model. Seventy-three, 2-week-old pigs were randomized into seven groups including five vaccinated and two control groups. Pigs in the vaccinated groups were vaccinated at 3 weeks (one dose) or at 3 and 6 weeks (two dose) of age. All vaccine regimens tested were effective in reducing naturally occurring PCV2 viremia at 16 weeks of age and after PCV2 challenge, demonstrating the capability of the products to induce a lasting protective immunity despite the presence of PCV2 viremia at the time of vaccination.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-77955514221&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.07.002

DO - 10.1016/j.vaccine.2010.07.002

M3 - Article

AN - SCOPUS:77955514221

VL - 28

SP - 5960

EP - 5966

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 37

ER -

Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this